Listen
VFEND (voriconazole), antifungal agent
INFECTIOUS DISEASE - New indication
Opinions on drugs -
Posted on
Feb 29 2016
Reason for request
Extension of Inclusion
No clinical benefit demonstrated when compared with NOXAFIL (posaconazole) as prophylaxis in haematopoietic stem cell transplant recipients at high risk for invasive fungal infections
- VFEND now has Marketing Authorisation in the prophylaxis of invasive fungal infections (IFI) in haematopoietic stem cell transplant recipients at high risk.
- No direct comparison has been made versus the other broad-spectrum antifungal agent, posaconazole (NOXAFIL) because of the concurrence of their development. An indirect comparison does not show a significant difference.
- The safety profile of VFEND reveals clinically significant abnormalities in liver function, vision disorders, and a risk of severe skin lesions or of cutaneous squamous cell carcinoma.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
